posted 10/24/02
Oral insulin absorption and elimination was much faster when
compared with subcutaneous injection.
Generex Biotechnology Corporation presented
promising data at the 38th annual meeting of the European Association for the
Study of Diabetes (EASD) in Budapest, Hungary, in September 2002.
The data suggest that Oralin, Generex'
proprietary oral insulin spray, may be a safe and effective replacement for
injected insulin in the treatment of type 1 and type 2 diabetes patients. Oralin
is delivered as a fine spray to the buccal (oral) cavity via Generex' RapidMist
device, where the formulation is rapidly absorbed through the buccal mucosa and
into the bloodstream.
The study entitled "Biokinetics of Oral Spray
Insulin: Comparison with Regular and Lispro Insulin in Patients with Type-1
Diabetes" found that the biokinetics of oral spray insulin was similar to lispro
insulin reaching peak plasma insulin levels 30 minutes after administration and
lowest levels at 240 min. As expected, regular insulin reached peak and steady
state levels between 30 and 120 min. Blood glucose levels declined following
insulin absorption independently of the type of insulin used. Oral spray insulin
was absorbed through the buccal mucosa with biookinetics similar to lispro
insulin.
The study entitled "Oral Insulin Spray as a Meal
Insulin in Treatment of Type-2 Diabetes" evaluated the efficacy of the Oralin
versus subcutaneous injection in controlling postprandial glucose in type-2
patients after a standard meal challenge. Results showed that the oral insulin
absorption and elimination was much faster when compared with subcutaneous
injection and outperformed subcutaneous injection in terms of glucose and
C-peptide lowering capacity as well as rise in the insulin levels.
The study entitled "Oral Insulin Spray (Oralin)
as Meal Insulin for Treatment of Type-1 Diabetes" evaluated the efficacy of the
Oralin spray in Type-1 patients after a standard meal challenge at
breakfast-time. Oralin spray at mealtime controlled glucose levels in a
comparable manner to s.c. injected insulin. The onset action of Oralin was much
faster and reached its peak level (Tmax) at 30 minutes. The rise in serum
insulin concentrations in the Oralin treated group was significantly higher
compared with s.c. injection. Orally absorbed insulin (Oralin) proved to be
efficient in controlling meal induced glucose excursion in type 1 patients.
Source: Diabetes In Control Dot Com.
Home - Table of Contents - Donate Now - About Diabetes - Warning Signs - Complications - Screening Test - Diabetes Terms - Site Search - Meet Mr. Diabetes® - Wake Up And Walk® Tour - Latest News - Headlines & News Stories - Health & Fitness - About Us - FAQ - Research Form - - Message Board - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us